APPX App Pharmaceuticals (MM)

APP Pharmaceuticals, Inc. (Nasdaq: APPX), a leading provider of hospital-based injectable pharmaceutical products, today said that the U.S Food and Drug Administration (FDA) has approved APP�s manufacturing facility in Barceloneta, Puerto Rico for the manufacture of three product codes of Heparin Sodium Injection, USP. �Bringing this third manufacturing site on-line is an important part of our commitment to ensuring that an uninterrupted and safe supply of heparin of the highest quality is available for U.S. patients,� said Tom Silberg, chief executive officer of APP Pharmaceuticals. �At the same time, we are now able to redeploy some of our manufacturing capacity at our two other facilities toward the production of other products to fulfill outstanding orders. I commend the team for working diligently to bring our Puerto Rico facility on-line quickly.� Silberg noted that, as a result of recent events in the heparin market, APP is currently the sole supplier of therapeutic heparin vials in the United States. APP has nine products manufactured at its Puerto Rico facility, including doxycycline, azithromycin and diphenhydramine. The company anticipates manufacturing more than 19 million units in Puerto Rico during 2008. Additionally, APP is conducting technical transfers and stability production in an effort to transfer over 25 additional product codes to this facility, which should translate to approximately 50 million units annually. About APP Pharmaceuticals, Inc. APP is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. The Company offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. Forward-Looking Statement The statements contained in this news release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this news release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the demand, supply and distribution of heparin. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, the availability and pricing of ingredients used in the manufacture of pharmaceutical products and the ability to successfully manufacture products in a time-sensitive and cost effective manner. Additional relevant information concerning risks can be found in APP Pharmaceuticals, Inc. Form 10-K for the year ended December 31, 2007 and other documents it has filed with the Securities and Exchange Commission. The information contained in this news release is as of the date of this release. APP assumes no obligations to update any forward-looking statements contained in this press release as the result of new information or future events or developments.